Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis ...

Pre-Exposure Prophylaxis (PrEP) is an HIV prevention strategy that enables HIV-negative people to stay HIV-negative by taking anti-HIV drugs (also called antiretrovirals, or "ARVs") before they are ...

HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF) or TDF–emtricitabine (FTC) has been shown to be effective against sexual and injection-drug related HIV ...

The FDA has approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the company hailed as a major breakthrough in the fight against the virus.

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect ...

The U.S. Food and Drug Administration (FDA) on June 18 approved a newly developed HIV/AIDS prevention drug that only needs to ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer viewer questions.